ALIM Alimera Sciences Inc.

0.5
-0.01  -2%
Previous Close 0.51
Open 0.52
Price To Book -1.04
Market Cap 35,429,247
Shares 71,000,495
Volume 322,373
Short Ratio
Av. Daily Volume 179,355

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
Iluvien
Diabetic macular edema

Latest News

  1. How Much Of Alimera Sciences, Inc. (NASDAQ:ALIM) Do Institutions Own?
  2. Alimera Announces ILUVIEN® Regulatory Approval in Australia for the Treatment of Diabetic Macular Edema
  3. Edited Transcript of ALIM earnings conference call or presentation 30-Jul-19 1:00pm GMT
  4. Alimera Sciences Announces Second Quarter 2019 Financial Results and Provides Corporate Update
  5. Alimera Sciences Announces Multiple Papers “On Demand” at the 2019 American Society of Retina Specialists Annual Meeting
  6. Alimera Sciences to Report Second Quarter Financial Results on Monday, July 29, 2019 and Provide Corporate Update
  7. Alimera Sciences Announces the Appointment of Industry Veteran and Ophthalmology Business Executive John Snisarenko to its Board of Directors
  8. Did Changing Sentiment Drive Alimera Sciences's (NASDAQ:ALIM) Share Price Down A Painful 85%?
  9. Alimera’s ILUVIEN® Receives Positive NICE Recommendation for Non-Infectious Posterior Uveitis
  10. Three-Year Clinical Trial Results Support ILUVIEN® Launch in Europe for the Prevention of Relapse in Recurrent Non-Infectious Uveitis Affecting the Posterior Segment
  11. Alimera Sciences Sees Hammer Chart Pattern: Time to Buy?
  12. Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign to Raise Awareness and Educate Consumers on Diabetic Macular Edema and ILUVIEN®
  13. Top Ranked Momentum Stocks to Buy for May 21st
  14. Alimera Sciences to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019
  15. Edited Transcript of ALIM earnings conference call or presentation 30-Apr-19 1:00pm GMT
  16. Alimera Sciences Announces First Quarter 2019 Financial Results and Provides Corporate Overview
  17. Alimera Sciences to Report First Quarter Financial Results on Monday, April 29, 2019 and Provide Corporate Update
  18. Alimera Sciences Announces Multiple Posters and a Podium Presentation of Clinical Data for ILUVIEN(R) to be Presented at the Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting
  19. Alimera Sciences Announces Expansion of Leadership Team with Appointment of Samer Kaba, MD as Chief Medical Officer
  20. Alimera Sciences Announces Approval Received in the Mutual Recognition Procedure for New Indication for ILUVIEN(R) in Europe